Reach Us +1-947-333-4405
Editor - David Rizzieri | Duke Cancer Institute | 20009
ISSN: 2167-0870

Journal of Clinical Trials
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

David Rizzieri

David Rizzieri
David Rizzieri, MD
Professor of Medicine
Chief, Section of Hematologic Malignancies
Associate Director for Clinical Research, Division of Hematologic Malignancies and Cellular Therapy
Duke Cancer Institute, USA
Tel: 919-668-1040
Email: [email protected]


As a translational researcher, he has focused his efforts on developing new therapies for patients with leukemia or lymphoma. He has been a member of the Combined International Bone Marrow Transplant Registry Lymphoma Writing Committee and is a member of the ALLIANCE (formerly CALGB) Leukemia Core Committee. He has served as chair or co-chair of multiple ALLIANCE lymphoma/ leukemia trials. He has led a team’s novel approaches for the care of patients using non-myeloablative allogeneic therapy to optimize a less toxic regimen for transplant of patients with hematologic malignancies using haplo-identical, as well as matched donors. This work is currently being extended with post-transplant graft manipulation studies focused on manipulating Natural Killer cell activity. He has led the development of anti-stromal therapy in lymphoma using new antibodies targeting the stromal protein, tenascin, and other early stage clinical studies. Further, He has served on various NIH/NHLBI grant review committees and the ASH sub-committee on Government Affairs. He oversees the development and conduct of all clinical trials in adults with hematologic malignancies conducted in the Duke Cancer Institute. In recognition of this leadership and success in our clinical research efforts, he was fortunate to receive the NIH ‘Clinical Investigator Team Leadership Award’ in 2010 and was awarded by the fellows the ‘Wendell Rosse Teaching Award’ in 2009.

Research Interest

Hematologic malignancies


Impediments to the Conduct of Clinical Research in our Current System and Suggestions-Improvements

Bortezomib Combined with Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-VFND) for the Treatment of Relapsed/Refractory Follicular Lymphoma

David Rizzieri
Editorial: J Clinic Trials 2012, 2: e110
DOI: 10.4172/2167-0870.1000e110
Anne W Beaven, Anthony D Sung, David Rizzieri and Zhiguo Li
Research Article: J Clinic Trials 2012, 2: 120
DOI: 10.4172/2167-0870.1000120